BMS’ Sotyktu Gains Traction with Rheumatologists Ahead of FDA Decision
Event summary
- One in three U.S. rheumatologists view BMS’ Sotyktu as a substantial advance in psoriatic arthritis (PsA) ahead of the March 6, 2026 FDA decision.
- Nearly half of surveyed rheumatologists are aware of the upcoming FDA decision, with Sotyktu being the most frequently cited pipeline therapy in PsA.
- Physicians estimate that roughly one-fifth of their PsA patients would be appropriate candidates for Sotyktu if approved.
- Sotyktu is expected to compete primarily with oral therapies like JAK inhibitors rather than biologic classes.
- BMS ranks lowest among rheumatologists’ top three most respected pharmaceutical partners in PsA.
The big picture
BMS’ Sotyktu is poised to enter a mature PsA treatment landscape dominated by biologics and JAK inhibitors. The drug’s potential approval represents a pivotal opportunity for BMS to reinforce its clinical differentiation and corporate standing in rheumatology. However, the company faces significant competition from established players like AbbVie, which is viewed as the strongest partner in PsA. The strategic importance of this launch extends beyond PsA, as deucravacitinib is also in development for systemic lupus erythematosus (SLE) and Sjögren’s disease, positioning rheumatologists at the center of its potential expansion into broader systemic autoimmune indications.
What we're watching
- Regulatory Outcome
- Whether the FDA approves Sotyktu for PsA and the potential impact on BMS’ market positioning.
- Market Penetration
- The pace at which Sotyktu gains adoption among rheumatologists and displaces existing oral therapies.
- Competitive Response
- How competitors like AbbVie, Pfizer, and Amgen react to Sotyktu’s entry and potential market share shifts.
Related topics